HURA - TuHURA Analyst Consensus Forecast

Symbol and logo of brand TuHURA (HURA)

The price action of TuHURA Biosciences, Inc. (HURA) on GURU.Markets reflects the current indicator 7.86. TuHURA Biosciences, Inc. (HURA) has established rapid delivery of biomaterials, avoiding supply chain delays. The business relies on creating personalized drugs for oncology centers, aiming to capture a share of the immuno-oncology market. Meanwhile, vaccine development is automated using AI, although final clinical trials remain under the control of medical specialists.

HURA: tuhurabio.com Analyst Consensus Forecast 07/04/2022 - 11/12/2026
Original product of TuHURA Biosciences, Inc.

To protect capital from volatility, it is essential for investors to compare the market price with the independent calculated value of the asset. Leveraging the human capital potential of TuHURA Biosciences, Inc. (HURA) in the field of onco-immunology, the market's target consensus trend aggregates expert forecasts on fair value, allowing for an assessment of the stock's growth potential through the lens of fundamental expectations for the company's future medical breakthroughs to ensure balanced portfolio management.

Competing companies

ONC (beigene.com) - Fair Value Consensus|Halozyme - Consensus Target|Analyst Consensus Forecast Revolution Medicines Inc RVMD|AAPG - Price Target Chart|Fair Value Consensus CGON (CG Oncology Therapeutics)|URGN: Analyst Consensus Forecast|bicara.com (BCAX) - Analyst Consensus Forecast|PSNL (Personalis) - Analyst Consensus Forecast|Consensus Target Erasca Inc (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast Y-mAbs Corp (YMAB)|Price Target Chart Aura Biosciences, Inc. AURA|CADL: Broker Consensus Forecast|Accuray - Analyst Consensus Forecast|SELLAS Life Sciences (SLS) - Consensus Target|ACTU: Analyst Consensus Forecast|Average Forecast Price Citius Oncology Inc (CTOR)|Price Target Chart Protara Therapeutics|FATE: Fair Value Consensus|Consensus Target WHWK (Aadi Bioscience Inc)|TCRX (tscan.com) - Fair Value Consensus|Analyst Consensus Forecast CSBR (Champions Oncology, Inc.)|XBIT - Consensus Target|CVM: Consensus Target|OSTX - Analyst Consensus Forecast|Radiopharm Theranostics Limited (RADX) - Price Target Chart|Artiva Biotherapeutics - Fair Value Consensus|ANL (Adlai Nortye Ltd) - Analyst Consensus Forecast|Average Forecast Price Veru Corporation VERU|Consensus Target TPST (Tempest Therapeutics)|Analyst Forecast Prices XLO|Renovaro - Consensus Target|Analyst Consensus Forecast Mural Oncology PLC MURA|Kairos Pharma Inc - Analyst Consensus Forecast|Fair Value Consensus OKUR (OnKure Therapeutics Inc)|GDTC (w2.cytomed.sg) - Consensus Target|Curis (CRIS) - Analyst Consensus Forecast|Price Target Chart Apollomics Inc.|THAR: Fair Value Consensus|Analyst Consensus Forecast ADVB|Analyst Consensus Forecast Genprex Inc (GNPX)|Calidi Biotherapeutics, Inc. - Consensus Target|Fair Value Consensus SBFM|Xenetic Bio - Analyst Consensus Forecast|SLRX: Price Target Chart|PPBT: Analyst Consensus Forecast|AONC - Analyst Median Target|Price Target Chart BeiGene, Ltd.|Average Forecast Price checkpointtx.com CKPT|Price Target Chart Elevation Oncology, Inc. (ELEV)|Analyst Median Target icadmed.com|Analyst Consensus Forecast IKNA (Ikena Oncology)|NTBL - Consensus Target|Viracta - Analyst Consensus Forecast|Analyst Median Target morphosys.com MOR|NAYA: Analyst Consensus Forecast|Average Forecast Price Ascentage Pharma Group International (AAPGV)